Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$0.13.

  • Lineage Cell Therapeutics' EPS (Basic) fell 55000.0% to -$0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.29, marking a year-over-year decrease of 14166.67%. This contributed to the annual value of -$0.09 for FY2024, which is 2264.96% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported EPS (Basic) of -$0.13 as of Q3 2025, which was down 55000.0% from -$0.13 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' EPS (Basic) registered a high of -$0.01 during Q1 2021, and its lowest value of -$0.17 during Q4 2021.
  • Its 5-year average for EPS (Basic) is -$0.05, with a median of -$0.03 in 2021.
  • The largest annual percentage gain for Lineage Cell Therapeutics' EPS (Basic) in the last 5 years was 8333.33% (2021), contrasted with its biggest fall of 180000.0% (2021).
  • Lineage Cell Therapeutics' EPS (Basic) (Quarter) stood at -$0.17 in 2021, then surged by 82.35% to -$0.03 in 2022, then grew by 8.99% to -$0.03 in 2023, then surged by 40.54% to -$0.02 in 2024, then plummeted by 700.77% to -$0.13 in 2025.
  • Its EPS (Basic) was -$0.13 in Q3 2025, compared to -$0.13 in Q2 2025 and -$0.02 in Q1 2025.